12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Company News  |  Deals

Sucampo, Takeda deal

Sucampo plans to exercise its right to pursue a performance audit of Takeda's U.S. marketing practices for Sucampo's Amitiza lubiprostone to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C)....

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >